We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 164.80 | 164.80 | 165.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/11/2016 12:44 | Vectura lack sufficient wholly-owned products which they acknowledge and are addressing. When in the future they own outright say 5-8 volume big margin products I would hope they appear attractive to a bid. 2020 on imo. | carpadium | |
30/11/2016 11:41 | About as much chance as there was of Glaxo buying SkyePharma i.e. 5% or less | aceuk | |
30/11/2016 11:19 | What are the chances of Novartis buying vec It would certainly save vec purchasing anybody to find a sales force | specul82 | |
29/11/2016 18:04 | Jdgen-VEC are keen to buy a company in the USA as MD said 'This time I would like to buy a company with an established U.S. sales force to accelerate the group's ambitions as it develops specialised lung drugs that are wholly owned by Vectura, rather than partnered with Big Pharma'. This intention was repeated during the presentation after the interims. This could be a major opportunity or a disaster, certainly it would be a time to reassess the merits of continuing to hold VEC shares. | alexchry | |
29/11/2016 16:54 | Don't think 250000 is a small trade after close | pooroldboy55 | |
29/11/2016 16:08 | pob: I am not sure its anyone in the know..more likely thin trading exacerbated by continual small sales by ex SKP shareholders taking some profit. alex: its all about ultibro!! if VEC buys own sales force company in USA I will probably sell out. You have to realise that Novartis must have known about potential review of GOLD but needed to wait for outcome before designing a marketing plan around it. The Ultibro head to head trial is just the icing on the cake (if successful). It will happen continues to be a strong hold and a strong buy at -140. | jdgen | |
29/11/2016 15:10 | The USA is the key for VEC. They are waiting for Novartis to make a decision re marketing of Ultibron, waiting for the decision in May regarding the Advair generic, waiting to take over a company already selling in the USA and, hopefully, still trying to find a partner to get Flutiform approved in the USA although I haven't seen any mention of this recently. VEC must be rather fed up with Novartis delaying their decision and unhappy with GSK re the litigation. It is no wonder that they want their own sales team in the USA. Certainly an interesting year ahead, let's hope a profitable one as well for shareholders. | alexchry | |
29/11/2016 15:05 | It's interesting how the share price drops back after any news is that because those in the know know something we don't know if you know what I mean !!!!!!!! | pooroldboy55 | |
29/11/2016 14:25 | And what happens to share price if they decide not to go ahead. | pooroldboy55 | |
29/11/2016 14:03 | 26th October, Novartis PR in New York told me they would have the results of the trial in four weeks.Presumably they are working through the data now and coming to a conclusion on whether and when to launch.With all the data from European trials and recognition of the GOLD report augers well.Dum spiro spero! | fhmktg | |
29/11/2016 13:57 | Great minds think alike! !!!!! | pooroldboy55 | |
29/11/2016 13:54 | Down again could do with some good news from Novartis, will we get it before end of year | pooroldboy55 | |
29/11/2016 13:49 | Come on Novartis, put us out of our misery.Christmas is coming for goodness sake! | fhmktg | |
27/11/2016 09:46 | Finally had the chance to go through the interims. Surprised the share price has held at such low level - 4p EPS in 6 months, so looking forward to the next full 12 month period (calendar 2017) and factoring in the additional top-line benefit from the SKP deal (PF revs were £15m ahead of reported) plus the growth then they should be hitting 10p EPS. Their long-term growth record also warrants a 20x-25x PE | adamb1978 | |
25/11/2016 20:28 | Seems to have resistance at 150, might bounce between 140 & 150 | tcarter66208 | |
25/11/2016 16:00 | alexchry... yep, I think you got it exactly right. The share price needs that announcement to push it on from this resistance level. | dontay | |
25/11/2016 14:26 | It's Black Friday so I can't understand why more shares haven't been snaffled up at these bargain prices! Perhaps it's because investors are waiting for the results of the Novartis test, they shouldn't be far away. | alexchry | |
25/11/2016 08:49 | Hi Richtea Yes could short but as they only cost me 73P via SKP had 100000 sold half so not to botherd. Cheers Martin ( POB ) | pooroldboy55 | |
24/11/2016 20:37 | As many might have suspected the interim results were obviously already priced in... the loss due to amortisation and the exceptional charge probably held it slightly back but the only real constraint on the share price at the moment is the delayed announcement from their best buddy... once thats done the chains are off. Analysts sentiment, regular news flow, new year tipsters etc.etc. should see the share price start to build over the next few months. By next May the full yr figures will be known, due to the 6 month comparison exercise on the merger WE pretty much ALREADY know they WILL be fine... so by next May sentiment should at a high level and VEC should have a great share price level for the future. GLA | dontay | |
24/11/2016 19:41 | Short it then oldboy and but back back in at 130. Seems sensible given your feeling. | richtea1701 | |
24/11/2016 17:37 | thmktg... yes, it's been known that GSK have been developing a triple formulation to replace Advair for years so it's nothing new. Also of course Advair hasn't gone anywhere... it's just patents that have expired. Presumably any Generic version will undercut Advair on price and THAT is where a Generic has the advantage. GSK's triple version will presumably have to marketed at a substantial cost so GSK can start to recover the years of R&D costs that have gone into it... unless Advair is withdrawn it will also be competing with it... advantage cheap Generic! There is nothing that can be done to expedite next May's regulatory announcement... It's a competitive market but I don't think there is any need to frightened of the competition. | dontay | |
24/11/2016 17:11 | GSK announced back in June that they intended to get this in by the end of the year so this is just confirmation. Providing our Generic version gets to market on time VEC will still be well ahead of the game and no doubt the GSK triple version will be at a substantially higher cost once they eventually get it to market! | dontay | |
24/11/2016 16:57 | After all GSKs competitors will have been aware that GSK's trials will have been underway. | fhmktg | |
24/11/2016 16:55 | You can bet that EVERYBODY will be pushing their teams to bring their plans forward tout de suite! | fhmktg | |
24/11/2016 16:41 | Not the best of days have a feeling this could go back to the low 130s no new news yesterday and GSK turning up the heat. | pooroldboy55 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions